Website profile

www.physiciansweekly.com

For nearly 40 years, Physician’s Weekly LLC, has been a trusted source of medical news and education for healthcare professionals.

  • 654articles · 365d
  • 2+ day agolatest article
  • Sep 17, 2025earliest in window
  • 94%with images
  • 248avg words
articles per day
Categories
  • Health & Wellness 648
  • Medical 633
  • Health 609
  • Science & Technology 19
  • Crime, Law & Justice 12
  • Crime & Law 8
  • Finance & Business 7
  • Disaster, Accident & Emergency Incident 2

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

www.PhysiciansWeekly.com
physiciansweekly.com > post > heart-failure-outcomes-under-asm-what-cardiologists-need-to-know

Heart Failure Outcomes Under ASM: What Cardiologists Need to Know

2+ day, 8+ hour ago   (91+ words) Under ASM’s group‑level assessment of care improvement activities, practices that integrate CCM into their HF workflow gain a meaningful structural advantage. The documentation discipline required for CCM—care plan maintenance, time tracking, and coordination records—also generates the evidence…...

Google News
physiciansweekly.com > post > patient-level-factors-drive-treatment-intensification-decisions-in-de-novo-mhspc

Patient-Level Factors Drive Treatment Intensification Decisions in De Novo mHSPC | www.PhysiciansWeekly.com

1+ week, 3+ day ago   (174+ words) Patient-Level Factors Drive Treatment Intensification Decisions in De Novo mHSPC In the complete cohort, most of the variation in treatment intensification was attributable to patient characteristics. Patients who were older had lower odds of intensification, as did patients who were…...

www.PhysiciansWeekly.com
physiciansweekly.com > post > primary-care-ai-assisted-diabetic-retinopathy-screening-shows-promise

Primary Care AI-Assisted Diabetic Retinopathy Screening Shows Promise

2+ week, 4+ day ago   (312+ words) Artificial intelligence (AI)–assisted diabetic retinopathy screening (DRS) in primary care demonstrated strong ability to rule out disease but produced substantial false positives, according to findings from a study published in the Scandinavian Journal of Primary Health Care. According to…...

www.PhysiciansWeekly.com
physiciansweekly.com > post > qa-inside-the-unique-risks-of-ophthalmic-anesthesia

Q&A: Inside the Unique Risks of Ophthalmic Anesthesia

3+ week, 1+ day ago   (292+ words) In the article, Dr. Nene and colleagues explored four key areas of challenge (intraoperative complications, postoperative challenges, patient comorbidities, and other features specific to ophthalmic anesthesia) and effective strategies to improve patient safety during procedures. To gain insights into practical…...

www.PhysiciansWeekly.com
physiciansweekly.com > post > abrocitinib-improves-disease-severity-itch-in-moderate-to-severe-atopic-dermatitis

Abrocitinib's Efficacy & Safety in Atopic Dermatitis

3+ week, 4+ day ago   (401+ words) The researchers identified five double-blind, placebo-controlled trials published between 2019 and 2021, involving a total of 1,927 patients. The studies enrolled adolescents and adults with moderate-to-severe AD and evaluated once-daily abrocitinib at doses of 100 mg or 200 mg over treatment periods ranging from 12 to…...

www.PhysiciansWeekly.com
physiciansweekly.com > post > peptides-promise-patience-letting-data-catch-up-to-hype

Peptides, Promise, & Patience: Letting Data Catch Up to Hype

3+ week, 4+ day ago   (375+ words) Alex McDonald, MD, CAQSM Peptides are having a moment. They are in your gym buddy’s fridge, in your favorite podcaster’s supplement stack, and on websites selling vials labeled “for research purposes only,” a disclaimer everyone knows is a wink. The…...

www.PhysiciansWeekly.com
physiciansweekly.com > post > early-trial-results-offer-hope-for-patients-with-cmt

Early Trial Results Offer Hope for Patients With CMT

1+ mon, 15+ hour ago   (431+ words) Approximately 125,000 people in the US have Charcot-Marie-Tooth disease (CMT). CMT is a group of hereditary disorders that damage the nerves. Most of the damage happens in the peripheral nerves, affecting the arms and legs. People with CMT experience a multitude…...

www.PhysiciansWeekly.com
physiciansweekly.com > post > new-fda-approval-expands-adhd-treatment-options

FDA Approves Centanafadine for ADHD

1+ mon, 1+ day ago   (66+ words) New FDA Approval Expands ADHD Treatment Options In a recent commentary, consultant pharmacist and regular contributor Yvette C. Terrie, RPh, BS Pharm, discussed the FDA’s approval of centanafadine for the treatment of attention-deficit/hyperactivity disorder (ADHD). Racism in Medicine: How One…...

www.PhysiciansWeekly.com
physiciansweekly.com > post > will-newly-approved-centanafadine-transform-adhd-care

Will Newly Approved Centanafadine Transform ADHD Care?

1+ mon, 5+ day ago   (297+ words) Among adults, ADHD more often manifests as inattention, emotional dysregulation, and executive dysfunction rather than overt hyperactivity, frequently delaying diagnosis as patients seek care for comorbid depression, anxiety, or substance use disorders.3 Across lifespans, ADHD may affect education, work, relationships,…...

Google News
physiciansweekly.com > post > ruxolitinib-cream-efficacious-in-moderate-ad-after-failure-of-standard-topicals

Ruxolitinib Shows Efficacy in Atopic Dermatitis | www.PhysiciansWeekly.com

1+ mon, 2+ week ago   (282+ words) Ruxolitinib Cream Efficacious in Moderate AD After Failure of Standard Topicals Adults with moderate atopic dermatitis (AD) who failed or could not tolerate topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) achieved significant clinical improvement with 1.5% ruxolitinib cream, according to…...